ERG and Lotus Clinical Research Merge

ERG has expanded its service offering to include specialized full-service CRO capabilities to satisfy its clients increasing demands, especially as it relates to early development services in the CNS market. Lotus Clinical Research, LLC joined the ERG portfolio in February of 2021. Founded in 2001 by Neil Singla, MD, an industry leading KOL in the strategic planning and execution of acute and chronic pain trials, Lotus built its reputation as a scientifically driven, niche CRO and site service provider. Specializing in strategic drug development, regulatory consulting services, and placebo response mitigation training Lotus has been instrumental in the development of many of the most important analgesic drugs approved over the past 20 years. Due to increasing demand for regulatory strategy, project management, biostatistics, data management, monitoring and other CRO services in acute and chronic pain and other CNS disorders, Lotus was eager focus more on its CRO business. The opportunity to merge with ERG and integrate its site network into the ERG site portfolio, and to have access to ERG’s 130+ bed phase 1 facility in Miami, was extremely attractive to Lotus. ERG’s strong presence in, and increased demand for, early phase clinical services required ERG’s management team to offer in-house full-service capabilities to its clients. The synergies and between ERG and Lotus were obvious to the management of both organizations, making it an easy decision to combine forces to offer client molecule-to-market capabilities.

Lotus highlights:

  • Specialty full-service CRO
  • Acute/ Chronic Pain and CNS
  • Proprietary Placebo Response Mitigation Training
  • Scientific and Regulatory Consulting
  • Clinical Development Planning

Visit »